Previous Close | 9.20 |
Open | 9.10 |
Bid | 0.00 x 80000 |
Ask | 0.00 x 70000 |
Day's Range | 9.10 - 9.52 |
52 Week Range | 8.53 - 15.61 |
Volume | |
Avg. Volume | 169 |
Market Cap | 17.009B |
Beta (5Y Monthly) | 0.29 |
PE Ratio (TTM) | 455.50 |
EPS (TTM) | 0.02 |
Earnings Date | Jul 30, 2024 - Aug 05, 2024 |
Forward Dividend & Yield | 0.45 (4.84%) |
Ex-Dividend Date | Sept 27, 2024 |
1y Target Est | N/A |
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO: Kristin Yarema, "Poseida") today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) has approved a label extension for XTANDI™ (enzalutamide) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy.
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), and Sumitomo Mitsui Banking Corporation (President & CEO: Akihiro Fukutome, "SMBC") today announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company. The new company will be dedicated to the incubation*1 of early drug discovery programs, primarily origin